RNA, U2 small nuclear 33, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-33P profile across patient tissues and cancer cell-line models. RNU2-33P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RNU2-33P is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, RNU2-33P RNA expression shows 11,734 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight OV, KIRC, and THYM as cancer lineages where RNU2-33P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-33P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-33P survival associations across molecular data types. RNU2-33P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-33P RNA expression–survival associations across cancer types. High RNU2-33P expression shows unfavorable associations in PAAD, THCA, HNSC and ESCA, but favorable associations in OV and KIRP. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify OV as the clearest survival context for RNU2-33P RNA expression.
This table summarizes RNU2-33P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-33P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-33P shows lower tumor expression in KIRC and COAD and higher tumor expression in UCEC and HNSC. The KIRC box plot shows higher RNU2-33P RNA expression in normal versus tumor tissue (log2 FC = −0.198, t-test p = .012).
This table shows molecular features associated with RNU2-33P in patient tissues and cancer cell lines. In patient samples, RNU2-33P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
